FDA Approves Andembry (garadacimab-gxii) for Prophylaxis to Prevent Attacks of Hereditary Angioedema
KING OF PRUSSIA, Pa., June 16, 2025 /PRNewswire/ -- Global biotechnology leader CSL today announced the U.S. Food and Drug Administration (FDA) approved Andembry (garadacimab-gxii), the only treatment targeting factor XIIa for prophylactic use to...
